The patent grant is a positive IP development but does not alter the company's near-term cash runway or clinical timeline. Monitor for IND filing updates and any partnership/licensing announcements that could monetize the platform. The stock's micro-cap status ($6M market cap) amplifies sensitivity to any news flow.
Price Chart
Executive Summary
Akari Therapeutics announced the grant of a major European patent (No. 3684773B1) providing broad composition-of-matter protection for its proprietary Thailanstatin-based ADC payloads across 39 European countries. This strengthens the company's intellectual property estate for its PH1 payload platform, which underpins its lead ADC candidates AKTX-101 (TROP2) and AKTX-102 (CEACAM5), but does not change the near-term clinical or financial outlook.
Key Facts
- European Patent No. 3684773B1 granted, titled 'Thailanstatin Analogs,' covering composition-of-matter for Akari's proprietary ADC payloads.
- Patent provides protection across 39 European countries, expanding global IP portfolio that already includes US, China, Japan, Australia, India, Mexico, and Israel patents.
- Lead candidate AKTX-101 (TROP2-targeting ADC) remains in IND-enabling studies with Phase 1 trial expected by mid-2027.
- AKTX-102 (CEACAM5-targeting ADC) is in preclinical development.
Financial Impact
No financial figures disclosed; patent grant is an IP milestone with no immediate revenue or cost impact.
Risk Factors
- No disclosed financial data — company remains pre-revenue with high cash burn risk.
- Phase 1 trial for AKTX-101 not expected until mid-2027, leaving a long period without clinical catalysts.
- Patent validity could be challenged; enforcement costs may be material for a micro-cap company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292856 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $7.63 (+1.19%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $7.63 (+43.14%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $7.63 (−46.31%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $7.63 (+26.71%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $7.63 (−65.40%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $7.63 (+57.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers